HALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial

Ian Roberts, Timothy Coats, Phil Edwards, Ian Gilmore, Vipul Jairath, Katharine Ker, Daniela Manno, Haleema Shakur, Simon Stanworth, Andrew Veitch, Ian Roberts, Timothy Coats, Phil Edwards, Ian Gilmore, Vipul Jairath, Katharine Ker, Daniela Manno, Haleema Shakur, Simon Stanworth, Andrew Veitch

Abstract

Background: Gastrointestinal bleeding is a common emergency that causes substantial mortality worldwide. Acute upper and lower gastrointestinal bleeding accounts for about 75,000 hospital admissions each year in the UK and causes the death of about 10% of these patients. Tranexamic acid has been shown to reduce the need for blood transfusion in surgical patients and to reduce mortality in bleeding trauma patients, with no apparent increase in thromboembolic events. A systematic review of clinical trials of upper gastrointestinal bleeding shows a reduction in the risk of death with tranexamic acid but the quality of the trials was poor and the estimates are imprecise. The trials were also too small to assess the effect of tranexamic acid on thromboembolic events.

Methods: HALT-IT is a pragmatic, randomised, double-blind, placebo-controlled trial which will determine the effect of tranexamic acid on mortality, morbidity (re-bleeding, non-fatal vascular events), blood transfusion, surgical intervention, and health status in patients with acute gastrointestinal bleeding. Eight thousand adult patients who fulfil the eligibility criteria will be randomised to receive tranexamic acid or placebo. Adults with significant acute upper or lower gastrointestinal bleeding can be included if the responsible doctor is substantially uncertain as to whether or not to use tranexamic acid in that particular patient. Trial treatment consists of a loading dose of tranexamic acid (1 g by intravenous injection) or placebo (sodium chloride 0.9%) given as soon as possible after randomisation, followed by an intravenous infusion of 3 g tranexamic acid or placebo (sodium chloride 0.9%) over 24 hours. The main analyses will compare those allocated tranexamic acid with those allocated placebo, on an intention-to-treat basis. Results will be presented as effect estimates with a measure of precision (95% confidence intervals). Subgroup analyses for the primary outcome will be based on time to treatment, source of bleeding (upper versus lower), suspected variceal bleeding and severity of bleeding. A study with 8,000 patients will have over 90% power to detect a 25% reduction in mortality from 10% to 7.5%.

Trial registration: Current Controlled Trials ISRCTN11225767 (registration date: 3 July 2012); Clinicaltrials.gov NCT01658124 (registration date: 26 July 2012).

Figures

Figure 1
Figure 1
Trial overview.
Figure 2
Figure 2
Consent procedure diagram.

References

    1. Button L, Roberts S, Evans P, Goldacre M, Akbari A, Dsilva R, MacEy S, Williams J. Hospitalized incidence and case fatality for upper gastrointestinal bleeding from 1999 to 2007. A record linkage study. Aliment Pharmacol Ther. 2011;33:64–76. doi: 10.1111/j.1365-2036.2010.04495.x.
    1. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut. 2011;60:1327–1335. doi: 10.1136/gut.2010.228437.
    1. Williams JG, Roberts SE, Ali MF, Cheung WY, Cohen DR, Demery G, Edwards A, Greer M, Hellier MD, Hutchings HA, Ip B, Longo MF, Russell IT, Snooks HA, Williams JC. Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut. 2007;56(Suppl 1):1–113. doi: 10.1136/gut.2006.117598.
    1. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003;86:125–139. doi: 10.1016/S0001-706X(03)00029-9.
    1. British Society of Gastroenterology . UK Comparative Audit of Upper Gastrointestinal Bleeding and the use of Blood. 2007.
    1. Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak R, Rahme E, Toubouti Y, Martel M, Chiba N, Fallone CA, RUGBE Investigators The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol. 2004;99:1238–1246. doi: 10.1111/j.1572-0241.2004.30272.x.
    1. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy V, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652–659. doi: 10.1002/hep.20339.
    1. D’Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599–612. doi: 10.1053/jhep.2003.50385.
    1. Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, Chan FK, Ng EK, You JH, Lee CW, Chan AC, Chung SC. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343:310–316. doi: 10.1056/NEJM200008033430501.
    1. Jairath V, Barkun A. Improving outcomes from acute upper gastrointestinal bleeding. Gut. 2012;61:1246–1249. doi: 10.1136/gutjnl-2011-300019.
    1. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering committee and members of the national audit of acute upper gastrointestinal haemorrhage. BMJ. 1995;311:222–226. doi: 10.1136/bmj.311.6999.222.
    1. Barnert J, Messmann H. Diagnosis and management of lower gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol. 2009;6:637–646. doi: 10.1038/nrgastro.2009.167.
    1. Farrell JJ, Friedman LS. Review article: the management of lower gastrointestinal bleeding. Aliment Pharmacol Ther. 2005;21:1281–1298. doi: 10.1111/j.1365-2036.2005.02485.x.
    1. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1997;92:419–424.
    1. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054. doi: 10.1136/bmj.e3054.
    1. The CRASH-2 Collaborators Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32. doi: 10.1016/S0140-6736(10)60835-5.
    1. The CRASH-2 Collaborators The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377:1096–1101. doi: 10.1016/S0140-6736(11)60278-X.
    1. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One. 2011;6:e18987. doi: 10.1371/journal.pone.0018987.
    1. WHO . Summary of the Report of the 18th Meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines. Geneva: World Health organization; 2011.
    1. Manno D, Ker K, Roberts I. How effective is tranexamic acid for acute gastrointestinal bleeding? BMJ. 2014;348:g1421. doi: 10.1136/bmj.g1421.
    1. Gluud LL, Klingenberg SL, Langholz E. Cochrane Database Syst Rev. 2012. Tranexamic acid for upper gastrointestinal bleeding.
    1. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–113. doi: 10.7326/0003-4819-152-2-201001190-00009.
    1. Sung JJ, Chan FK, Chen M, Ching JY, Ho KY, Kachintorn U, Kim N, Lau JY, Menon J, Rani AA, Reddy N, Sollano J, Sugano K, Tsoi KK, Wu CY, Yeomans N, Vakil N, Goh KL, Asia-Pacific Working Group Asia-pacific working group consensus on non-variceal upper gastrointestinal bleeding. Gut. 2011;60:1170–1177. doi: 10.1136/gut.2010.230292.
    1. National Institute for Health and Clinical Excellence . Management of Acute Upper Gastrointestinal Bleeding (Clinical Guideline 141) 2012.
    1. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet. 1993;342:891–894. doi: 10.1016/0140-6736(93)91945-I.
    1. Prentice CR. Basis of antifibrinolytic therapy. J Clin Pathol Suppl. 1980;14:35–40. doi: 10.1136/jcp.33.Suppl_14.35.
    1. Al-Mohana JM, Lowe GD, Murray GD, Burns HG. Association of fibrinolytic tests with outcome of acute upper-gastrointestinal-tract bleeding. Lancet. 1993;341:518–521. doi: 10.1016/0140-6736(93)90278-O.
    1. Poller L, Thomson J. Evidence for a relationship between fibrinolysis and haematemesis. Br J Haematol. 1973;24:664.
    1. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57:1005–1032. doi: 10.2165/00003495-199957060-00017.
    1. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thoracic Surg. 2012;93:148–154. doi: 10.1016/j.athoracsur.2011.07.085.
    1. Manji RA, Grocott HP, Leake J, Ariano RE, Manji JS, Menkis AH, Jacobsohn E. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anesthesia. 2012;59:6–13. doi: 10.1007/s12630-011-9618-z.
    1. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesthesia Analgesia. 2010;110:350–353. doi: 10.1213/ANE.0b013e3181c92b23.
    1. Keyl C, Uhl R, Beyersdorf F, Stampf S, Lehane C, Wiesenack C, Trenk D. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardio Thorac. 2011;39:e114–e121. doi: 10.1016/j.ejcts.2010.12.030.
    1. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ. 1998;317:1170–1171. doi: 10.1136/bmj.317.7167.1170.
    1. Straube S, Tramer MR, Moore RA, Derry S, McQuay HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;9:41. doi: 10.1186/1471-230X-9-41.
    1. Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K. Cochrane Database Syst Rev. 2011. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
    1. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose–response relationship of tranexamic acid. Anesthesiology. 1995;82:383–392. doi: 10.1097/00000542-199502000-00009.
    1. Wallace M, Shelkey M. Monitoring functional status in hospitalized older adults. Am J Nurs. 2008;108:64–71. doi: 10.1097/01.NAJ.0000314811.46029.3d.
    1. DAMOCLES study group A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365:711–722. doi: 10.1016/S0140-6736(05)17965-3.
    1. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971;44:793–797. doi: 10.1259/0007-1285-44-526-793.
    1. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1–39. doi: 10.1038/bjc.1977.1.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194. doi: 10.1016/S0140-6736(00)04337-3.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner